Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...
A. Giménez-Capitán, D. Olmo-González, E. Martínez-Pérez et al.· Annals of Translational Medi...· 0 citations
Melanoma has one of the highest propensities to metastasize to the brain, and despite major advances with immune checkpoint inhibitors, brain metastases remain a leading cause of morbidity and mortality. The biological mechanisms governing brain colonization, immune evasion, and resistance to therapy are incompletely u...
R. Rosell, M. González-Cao, D. Olmo-Gónzalez et al.· Annals of Translational Medi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.